BBIO · BridgeBio Pharma, Inc.
$68.15
-0.60% last session
End-of-day data · close of 2026-10-26
Market cap
$13B
Enterprise value
$16B
Trailing P/E
—
Forward P/E
-305.2
Dividend yield
0.0%
Beta
0.97
Avg volume
2M
Employees
1K
Daily Change %
-0.60%
5 Days Change
2.61%
10 Days Change
7.61%
30 Days Change
3.67%
60 Days Change
-15.97%
Month to Day Change
1.81%
Year to Day Change
-10.94%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BBIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Morgan Stanley
Overweight$87.00
+26.9% vs priceCitigroup
Neutral$91.00
+32.7% vs priceBarclays
Overweight$156
+127.5% vs priceJP Morgan
Overweight$111
+61.9% vs priceBank of America
Buy$104
+51.7% vs priceWells Fargo
Overweight$102
+48.8% vs priceRBC Capital
Outperform$100
+45.9% vs priceGoldman Sachs
Buy$100
+45.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Maintains | Overweight | $97.00 → $87.00 |
| 2026-10-19 | Citigroup | Maintains | Neutral | $94.00 → $91.00 |
| 2026-10-19 | Piper Sandler | Maintains | Overweight | $115 → $120 |
| 2026-10-07 | Barclays | Maintains | Overweight | $157 → $156 |
| 2026-09-10 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-09-02 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-09-01 | Mizuho | Maintains | Outperform | $96.00 → $110 |
| 2026-08-12 | Truist Securities | Maintains | Buy | $102 → $107 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 4.2% below the 50-day MA ($71.15).
- bearish: Price vs 200-day MA: Trading 6.5% below the 200-day MA ($72.87).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.68) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($54.26) and high ($90.17).
BBIO Price Chart
Loading chart for BBIO…
Fundamentals
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.